The project intends to carry out a retrospective study on the epidemiology, predisposingfactors, clinical manifestations, diagnosis, treatment, prognosis and economic burden ofmucormycosis in a Chinese single-center allogeneic hematopoietic stem celltransplantation population. The project was conducted at the Blood Diseases Hospital,Chinese Academy of Medical Sciences, which has rich experience in hematopoietic stem celltransplantation and has completed more than 3,000 cases of various types of HSCT, 400allogeneic hematopoietic stem cell transplants per year, and routine bronchoscopy andapplication of guideline-recommended regimens for the treatment of mucormycosis. Thisstudy will objectively reflect the current management status of allogeneic hematopoieticstem cell transplantation combined with mucormycosis in Chinese transplant centers.Through systematic analysis of the changes in the management of mucormycosis in Chinesepatients undergoing hematopoietic stem cell transplantation, to gain perspective into theimpact of Covid19, diagnostic techniques, and new drugs on the incidence, diagnosis andtreatment of mucormycosis . This will has a profound impact on optimizing the managementstrategies of mucormycosis in patients undergoing hematopoietic stem cell transplantationin the future.
Divide the patients into pre-covid 19 group(2015.01-2019.12) and covid 19
group(2020.1-2023.12) according to the time period.
Objectives:
1.Conduct a comparative analysis in 2015-2020 stage (Pre-Covid Era) and 2020-2024 stage
(Covid Era). To summarize and compare the characteristics of Mucormycosis in Chinese
hematologic malignancies population from the aspects of incidence, mucorus species, types
of mucormycosis, diagnostic techniques, treatment methods (surgical +drugs),
pharmaceutical economics and prognosis between two stages. Objectively reflect the
current management status of Mucormycosis in this population.
2 Analyze the possible causes of the epidemiology changing of mucormycosis: COVID19
influence, the advancement of diagnostic technology(NGS, respiratory endoscope
intervention technique etc.) and other factors.
3 Impact of treatment progress on disease prognosis and burden: the status of surgery
changes; To investigate the efficacy, safety and therapeutic status of posaconazole and
other antifungal drugs in the treatment of Mucormycosis, and analyze the impact of the
new antifungal drugs on the prognosis.
Data collection:
According to the information provided in the medical records and test results, enter the
relevant data: including baseline characteristics, complications, clinical
manifestations, laboratory tests, bronchoscopy results, imaging findings, fungal
prophylaxis medication, therapeutic medication, surgical conditions and prognosis.
Results:
1. Incidence difference of invasive mucormycosis between two stages;
2. Risk factors difference of invasive mucormycosis between two stages;
3. Difference of Clinical types, imaging features and bronchoscopic features of
invasive mucormycosis in hematologic malignancies between two stages;.
4. Changing of etiology and histopathological results of invasive mucormycosis in
hematologic malignancies between two stages;.
5. History of antifungal drug exposure in hematologic malignancies patients with
invasive mucormycosis;
6. Treatment regimen and course changing of invasive mucormycosis
7. Prognosis of invasive mucormycosis in hematologic malignancies patients;
8. Economic burden transition of invasive mucormycosis in hematologic malignancies
patients including average length of hospital stay, cost of antifungal therapy etc.
9. Incidence and characteristics of invasive pulmonary mucormycosis in allogeneic
hematopoietic stem cell transplantation patients during two stages.
Inclusion Criteria:
1. Patients with hematologic diseases who undergoes hematopoietic stem cell
transplantation in the center from January 2015 to December 2023.
2. Age≥18 years old.
3. Patients who were diagnosed with mucormycosis(proven or probable) in accordance with
the 2008 EORTC/MSG criteria and Revised EORTC/MSGERC 2020 Criteria.[8][9].
4. The patients themselves or their authorized clients agree to participate in the
clinical study and sign the informed consent.
Exclusion Criteria:
1. Patients with fungal infections other than mucormycosis were excluded.
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, China
Not Provided